Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Peg-IFNα2b and Anti-PD-1 in Advanced Solid Tumors
NCT07438093Phase 1Not yet recruiting
- Sponsor
- First Affiliated Hospital of Xiamen University
- Start
- Apr 2026
- Primary completion
- Apr 2027
- Modality
- Polymer-based Nanoparticles, Cytokines & Interferons
- Countries
- 1
01
Overview
Phase 1, open-label trial of peginterferon alfa-2b in solid tumor (3 cohorts), sponsored by First Affiliated Hospital of Xiamen University. Primary endpoints: Incidence of Dose-Limiting Toxicities at 21 days, Incidence of Treatment-Emergent Adverse Events up to 24 months and 1 more. Planned start Apr 2026; status: not yet recruiting.
02
Drugs
peginterferon alfa-2b
03
Conditions
solid tumor
Beyond the preview
Go deeper on NCT07438093.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07438093.